Suppr超能文献

影响肝细胞癌活体肝移植术后复发及生存的因素。

Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.

作者信息

Abdel-Wahab Mohammed, Sultan Ahmad M, Fathy Omar M, Salah Tarek, Elshobary Mohammed M, Elghawalby Nabieh A, Yassen Amr M, Elsarraf Walid M R, Elsaadany Mohammed F, Zalatah Khaled

出版信息

Hepatogastroenterology. 2013 Nov-Dec;60(128):1847-53.

Abstract

BACKGROUND/AIMS: HCC is a leading cause of cancer-related deaths worldwide. The main etiological factor in Egypt is HCV infection. Lack of cadaveric transplantation in Egypt makes LDLT the only available option for liver transplantation for HCC patients with advanced cirrhosis and/or non-resectable tumors.

METHODOLOGY

Between January 2004 and April 2012, 170 patients underwent LDLT at the Liver Transplantation Unit, Mansoura University, and 52 (30.6%) were shown to have HCC by pathological examination. Patient demographics, preoperative interventions and pathological findings were evaluated for their influence on recurrence and survival. Patients were followed-up with abdominal sonography and AFP every 3 months and CT scans every 6 months. Median follow-up was 22.9 months.

RESULTS

The main cause of underlying cirrhosis was HCV (96.2%). One or more different pre-transplant treatments of HCC were performed in 14 (27.4%) patients. The median total size was 4cm (0.8-15.5). Microvascular invasion was detected in 16 (31.4%) patients; 16 patients proved to have tumors beyond the Milan criteria. Pre-transplantation AFP more than 200ng/mL, total tumor size more than 8cm and microvascular invasion influenced recurrence rate on univariate analysis. Multivariate analysis identified AFP (p = 0.016) as independent factor for recurrence. Survival was significantly affected by AFP (p = 0.003) and microvascular invasion (p = 0.003).

CONCLUSIONS

LDLT is a feasible option for patients with HCC on top of cirrhosis with good survival and recurrence-free survival rates.

摘要

背景/目的:肝癌是全球癌症相关死亡的主要原因。埃及的主要病因是丙型肝炎病毒感染。由于埃及缺乏尸体供肝移植,对于晚期肝硬化和/或不可切除肿瘤的肝癌患者,活体肝移植是唯一可行的肝移植选择。

方法

2004年1月至2012年4月,170例患者在曼苏拉大学肝移植科接受了活体肝移植,其中52例(30.6%)经病理检查证实患有肝癌。评估患者的人口统计学特征、术前干预措施和病理结果对复发和生存的影响。每3个月对患者进行腹部超声和甲胎蛋白检查随访,每6个月进行CT扫描。中位随访时间为22.9个月。

结果

潜在肝硬化的主要原因是丙型肝炎病毒(96.2%)。14例(27.4%)患者在移植前接受了一种或多种不同的肝癌治疗。肿瘤总大小的中位数为4cm(0.8 - 15.5)。16例(31.4%)患者检测到微血管侵犯;16例患者的肿瘤超出了米兰标准。单因素分析显示,移植前甲胎蛋白超过200ng/mL、肿瘤总大小超过8cm和微血管侵犯影响复发率。多因素分析确定甲胎蛋白(p = 0.016)是复发的独立因素。甲胎蛋白(p = 0.003)和微血管侵犯(p = 0.003)对生存有显著影响。

结论

对于合并肝硬化的肝癌患者,活体肝移植是一种可行的选择,具有良好的生存率和无复发生存率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验